Wounded Marine and His Family to Receive Life-Changing Home Makeover on Military Makeover with Montel®
The Reeves Family of North Carolina to Be Featured in Upcoming Season Airing on Lifetime TV.
Full makeover will be realized between June 10th to June 22nd.
The reveal of the home makeover will be filmed on June 22nd.
KING, N.C. , May 28, 2025 /PRNewswire/ -- Military Makeover with Montel® along with Official Non-Profit Partner, Purple Heart Homes, proudly announces its upcoming season spotlighting the remarkable story of U.S. Marine Corps veteran Sean Reeves and his family. Coming to Lifetime TV this summer, this season will follow an inspiring path of bravery, dedication, and recovery, culminating in a well-earned home makeover for a selfless family. Sean's courageous service and sacrifice were recognized with many military decorations, such as the Purple Heart, Combat Action Ribbon, Presidential Unit Citation, NATO Medal ISAF Afghanistan, and the Afghanistan Campaign Ribbon, among others.
Driven by the September 11th attacks, Sean Reeves enlisted in the United States Marine Corps upon his 2008 high school graduation. He served as an infantry rifleman (0311) with the First Battalion, Second Marines and was deployed to Afghanistan in 2010. During Operation Northern Penetration, Mr. Reeves sustained a traumatic brain injury (TBI) and three gunshot wounds resulting from an improvised explosive device (IED) detonation and subsequent ambush. Despite these severe injuries, he continued his military service until his medical retirement in 2011.
Presently, Mr. Reeves is employed as a Care Coordinator at Veterans Bridge Home, providing support to veterans and their families as they navigate challenging transitions. Notwithstanding persistent chronic pain, cognitive impairments, post-traumatic stress disorder (PTSD), and having achieved remission from non-Hodgkin lymphoma, he remains a dedicated advocate and an essential source of support within the veteran community.
"The story of the Reeves family is one of resilience and commitment to community," said Nicole Oropesa, President of BrandStar Entertainment. "Through Military Makeover with Montel, we are honored to recognize and uplift a family who truly embodies the heart of service to their fellow veterans."
With the help of generous partners and the King, NC community, alongside Co-Host Art Edmonds and Designer Jennifer Bertrand, Military Makeover with Montel® will renovate the Reeves family home to reflect the care, accessibility, and comfort they deserve.
To volunteer, click here.
Military Makeover with Montel: Military Makeover with Montel® is an award-winning reality TV series dedicated to transforming the homes and lives of military families across the country. Hosted by Veteran, Author and TV Personality Montel Williams, alongside Co-Host Art Edmonds and Designer Jennifer Bertrand, the show brings together businesses, non-profits, and local communities to create lasting change for those who've served. Airing on Lifetime® and the American Forces Network, Military Makeover is more than a renovation show—it's a powerful mission where help, healing, and hope truly start at home. For more information, visit www.MilitaryMakeover.tv
Purple Heart Homes: Purple Heart Homes is a 501(c)3 nonprofit organization founded by John Gallina and the late Dale Beatty, two Iraq combat-wounded Veterans who started a mission to provide housing solutions for Service-Connected Disabled Veterans and their families. Driven by the belief that no Veteran should be left behind, Purple Heart Homes, together with the community, is committed to ensuring quality of life solutions for Disabled American Veterans from all eras. Purple Heart Homes – Improving Veterans' Lives One Home at a Time.For more information, visit www.phhusa.org and follow us on X @PHHTweet and Facebook and Instagram @PurpleHeartHomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/wounded-marine-and-his-family-to-receive-life-changing-home-makeover-on-military-makeover-with-montel-302467485.html
SOURCE Military Makeover with Montel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
CCTV+: 2025 Taklimakan Rally Concludes After thrilling 13-Day Desert Challenge
BEIJING, June 2, 2025 /PRNewswire/ -- The X Power 2025 Taklimakan Rally wrapped up with roaring success on June 1 in northwest China's Xinjiang. Kicking off on May 20, the grueling 13-day event spanned Aksu, Hetian, and Kashi prefectures. This year's course covered a total of 5,183 kilometers, including 2,200 kilometers of timed special stages across deserts, Gobi plains, and river crossings. A total of 23 motorcycles and 105 vehicles participated, with 233 racers from 12 countries battling extreme heat and complex terrain. Czech rider Martin Michek and China's Liu Yangui claimed overall victories in the motorcycle and car categories, respectively. Michek clinched the motorcycle title with a total time of 28 hours, 31 minutes, and 4 seconds, leading a commanding performance by his team. "This race was extremely tough, but I really enjoyed competing in China," said Michek, who participated in the rally for the first time. Liu secured the car division crown with a time of 27 hours, 8 minutes, and 15 seconds. "Winning the overall title was our only goal, and it's the greatest recognition we could receive," Liu said, expressing gratitude to his team and all support staff. Known as "China's Dakar," the Taklimakan Rally is widely regarded as the country's most challenging cross-country rally. Since its inception in 2005, the event has continued to evolve. This year marked the debut of a New Energy Vehicle (NEV) category, with ten vehicles entering the T2.E class. In this inaugural NEV category, Yao Weiqiang of the Great Wall Tank Hi4 Team took the title, finishing in 37 hours, 30 minutes, and 42 seconds. The closing ceremony featured a spectacular drone performance and fireworks show, bringing celebration and relief after 13 intense days. Racers, mechanics, and support crews finally had a moment to breathe, reflect, and enjoy the joy of victory and achievement. View original content to download multimedia: SOURCE CCTV+ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
SUZHOU, China, June 3, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors. Title: JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trialsAbstract Number for Publication: 5557Session Type and Title: Poster Session - Gynecologic CancerSession Date and Time: 6/1/2025 9:00 AM-12:00 PM CDTPresenter: Xiaohua Wu, Fudan University Shanghai Cancer Center Methods JSKN003-101 (NCT05494918) is a Phase I study in Australia and JSKN003-102 (NCT05744427) is a Phase I/II study in China. Both trials enrolled patients with advanced solid tumors who were to receive JSKN003 monotherapy at various dose levels. Pooled results have demonstrated that JSKN003 monotherapy has promising efficacy signals in patients with PROC, and the efficacy was observed across patients with (IHC 1+/2+/3+) or without (IHC 0) HER2 expression, with or without prior bevacizumab and prior PARP inhibitor. Preliminary data from the pooled analysis of these two studies were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time. The latest findings for non-primary platinum-refractory PROC patients at a longer follow-up time were reported at this ASCO Annual Meeting. Results As of February 28, 2025, 46 PROC patients were enrolled and received JSKN003 every three weeks across five doses levels, among which 2 patients at the dose of 4.2 mg/kg, 2 patients at the dose of 5.2 mg/kg, 40 patients at the dose of 6.3 mg/kg (RP2D), 1 patient at the dose of 7.3mg/kg, and 1 patient at the dose of 8.4mg/kg. Efficacy: With a median follow-up time of 9.3 months, 46 patients were efficacy evaluable. 42 patients (91.3%) exhibited tumor shrinkage. The objective response rate (ORR) was 63.0%, the median progression-free survival (PFS) was 7.7 months, and the 9-month overall survival (OS) rate was 89.9%. Efficacy was observed across different HER2-expression subgroups. The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+). Safety: Grade 3-4 treatment-related adverse events (TRAEs) occurred in 9 patients (19.6%). Serious TRAEs were reported in 6 patients (13.0%). No TRAEs leading to death. Interstitial lung disease (ILD) was observed in 5 patients (10.9%), all were Grade 1/2. Conclusions With extended follow-up, JSKN003 demonstrated robust PFS improvement in PROC, along with early signals of OS benefit. A confirmatory trial (JSKN003-306, NCT06751485) is currently enrolling all comers regardless of HER2 expression to validate JSKN003 as a treatment option for this patient population. Title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studiesAbstract Number for Publication: 1028Session Type and Title: Poster Session - Breast Cancer - MetastaticSession Date and Time: 6/2/2025 9:00 AM-12:00 PM CDTPresenter: Yiqun Du, Fudan University Shanghai Cancer Center Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-positive (IHC 3+ or 2+/ISH+) advanced breast cancer from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, the median follow-up duration was 6.1 months. A total of 88 patients with HER2-positive breast cancer were enrolled, with the majority receiving 6.3 mg/kg or 8.4 mg/kg doses. The median age was 55 years (range: 32-79), with 77.3% ECOG PS 1. All patients had stage IV disease, with 76.1% having visceral metastases. All patients had prior anti-HER2 therapy, including 85.2% with prior ADCs or TKIs, and 55.7% having at least three prior lines treatment. Efficacy: A total of 80 T-DXd-naïve patients were enrolled, of whom 75 were evaluable for efficacy. In this population (N=75), JSKN003 demonstrated a confirmed ORR of 54.7% (95% CI: 42.7-66.2). The disease control rate (DCR) and clinical benefit rate (CBR) were 94.7% and 66.7%, respectively. Among 30 patients treated at the RP2D of 6.3 mg/kg, the confirmed ORR was 73.3%, and CBR reached 83.3%. Subgroup analyses by line of therapy showed ORRs of 66.7% in the prior first line group of 15 patients and 63.2% in the prior second line group of 19 patients, respectively. In addition, 8 patients who had previously received T-DXd were enrolled, among whom 7 had evaluable efficacy data. One patient achieved a partial response (PR), four had stable disease (SD), and tumor shrinkage was observed in four patients. These patients were analyzed separately for exploratory purposes. The median duration of response (DoR) in the overall population was 18.4 months (95% CI: 9.9-NE). Median PFS was not mature at the time of data cutoff. The 3-month and 6-month PFS rates were 88.4% (95% CI: 78.8–93.8) and 75.4% (95% CI: 62.3–84.4), respectively. Safety: 15.9% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 5.7% of patients. Dose reductions due to TRAEs occurred in 12.5% of patients, and one patient discontinued due to a TRAE. No TRAEs led to death. The most common TRAEs (≥20%) were nausea, increased alanine aminotransferase, decreased white blood cell count, vomiting, anemia, decreased appetite, thrombocytopenia, fatigue, neutropenia, and diarrhea. ILD was reported in 4 patients (4.5%), mostly Grade 1-2; one case was Grade 3. Conclusions JSKN003 demonstrated promising antitumor activity and manageable safety in heavily pretreated HER2-positive breast cancer, including patients previously treated with T-DXd. Its biparatopic HER2 antibody design may enhance target binding and contribute to the observed clinical benefit. A pivotal Phase III trial (JSKN003-301, NCT06846437) is ongoing to compare JSKN003 with T-DM1 in patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab. Title: A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumorsAbstract Number for Publication: 3022Session Type and Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor BiologySession Date and Time: 6/2/2025 1:30 PM-4:30 PM CDTPresenter: Dan Liu, Beijing Cancer Hospital Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-overexpressing (IHC 3+) metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJC) and colorectal cancer (CRC) patients from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, a total of 50 patients with HER2-overexpressing gastrointestinal tumors (27 patients in GC/GEJC and 23 patients in CRC) were enrolled and treated with JSKN003 monotherapy across 7 dose levels: 1 patient at the dose of 2.1 mg/kg, 1 patient at the dose of 4.2 mg/kg, 1 patient at the dose of 5.2 mg/kg, 43 patients at the dose of 6.3 mg/kg, 1 patient at the dose of 7.3 mg/kg, 2 patients at the dose of 8.4 mg/kg and 1 patient at the dose of 10.5 mg/kg. The median age was 60 years (range: 52-66), with 86.0% ECOG PS 1. Most patients were heavily pretreated: 38.0% had at least three lines of prior therapies, 68.0% received anti-HER2 therapy, 48.0% received Irinotecan. Efficacy: Among 48 patients who had at least one tumor assessment after baseline, JSKN003 demonstrated the ORR of 62.5% and the DCR was 93.8%. Among 27 patients with GC/GEJC, the ORR was 63.0% and DCR reached 92.6%. Among 21 patients with CRC, the ORR was 61.9% and DCR reached 95.2%. Among twenty patients with BRAF V600E-wild type, the ORR was 65.0%. Additionally, among 24 patients (4 patients in GC/GEJC and 20 patients in CRC) who were pretreated with irinotecan, the ORR achieved 58.3%. The median DoR in GC/GEJC patients was 9.6 months (95% CI: 3.0-NE), while the median DoR in CRC patients was 12.1 months (95% CI: 5.8-NE). Median PFS was 9.6 months (95%CI: 4.3, 11.6) with 70.4% PFS rate at 6 months in GC/GEJC patients. Median PFS was 13.8 months (95% CI: 6.8, NE) with 88.9% PFS rate at 6 months in CRC patients. Safety: 18.0% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 6.0% of patients. Dose reduction due to TRAEs occurred in 20.0% of patients and 16.3% at RP2D. No TEAEs led to discontinuation or death. The most common TRAEs (≥20%) were nausea, diarrhea, decreased appetite, decreased white blood cell count, anemia, fatigue, decreased neutrophil count, decreased platelet count and vomiting. ILD was reported in 3 patients (6.0%), with Grade 1 in 2 patients and Grade 2 in 1 patient. Conclusions JSKN003 demonstrated promising efficacy in heavily pretreated HER2-overexpressing (IHC3+) gastrointestinal tumors including patients previously treated with irinotecan, with a manageable and predictable safety profile. The HER2 biparatopic ADC design may contribute to the observed clinical benefit. About JSKN003 JSKN003 is a bispecific ADC developed based on KN026 using Alphamab's proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
AmphiStar and Kensing Announce Strategic Partnership to Bring Upcycled Biosurfactants to the North American Personal Care Market
Partnership delivers localized access to 100% upcycled biosurfactants with significantly reduced environmental impact, while advancing novel designer molecule development. GHENT, Belgium and KANKAKEE, Ill., June 2, 2025 /PRNewswire/ -- Belgian biotech innovator AmphiStar, a pioneer in 100% upcycled microbial biosurfactants and Kensing, a leading North American producer of high-purity surfactants, and the global leader in upcycled plant-based vitamin E and sterols, today announced a strategic partnership to deliver sustainable, next-generation biosurfactants to the North American personal care market. As part of this collaboration, AmphiStar's next-generation biosurfactants, produced by microbial fermentation of repurposed agri-food side streams, will be launched into the North American market by Kensing in an exclusive partnership. Leveraging its deep surfactant expertise and established market access, Kensing will play a critical role in driving adoption across the Personal Care and HI&I Industries. Kensing will work with AmphiStar to develop regionally sourced circular feedstocks from biobased waste and sidestreams, such as plant oils from Kensing's production, with a near-term plan to fully onshore production in the US. This will not only reduce transport-related emissions but will also allow the partners to build a resilient, decentralised supply chain aligned with evolving customer expectations. The products offer performance for formulators seeking to develop mild and sustainable formulations. They can be used as emulsifiers and co-surfactants in body lotions, creams, shampoos, body wash, make-up remover and other products. Kensing and AmphiStar will also co-develop AmphiStar's recently launched library of 80+ sustainable and unique 'designer' biosurfactant platform technology, with the shared goal of further developing and commercializing high-potential innovations in the personal care, agrochemical and HI&I markets. "Kensing's scientific expertise in formulation and production of plant-based ingredients coupled with our novel biomanufacturing technology platform make this an ideal and complementary partnership that will not only help us bring our sustainable biosurfactants to the North American market, but also see us jointly develop and launch new ones in the future", said Pierre-Franck Valentin, CEO of AmphiStar. "This partnership with AmphiStar reflects Kensing's bold commitment to leapfrog into the next generation of biosurfactants," said Serge Rogasik, President and CEO of Kensing. "By combining AmphiStar's cutting-edge upcycled biosurfactant technology with Kensing's industrial scale and market reach, we are unlocking a new era of high-performance biosurfactants—formulated from upcycled biowaste, free from conventional feedstock constraints, and offering both formulation versatility and the potential for highly competitive economics at scale."AmphiStar's biosurfactants are the result of an IP-backed breakthrough technology featuring an unprecedented combination in the surfactant landscape: advanced synthetic biology, waste processing and continuous biomanufacturing eliminating reliance on fossil feedstocks and resource-intensive crops, AmphiStar's technology delivers a significantly enhanced and novel sustainability profile. A recent LCA study (March 2025) revealed the exceptional sustainability profile of AmphiStar's biosurfactants compared to both conventional chemical-based and existing biosurfactants, including a four-fold reduction in CO2 equivalent emissions, an 18-fold reduction in water deprivation, a 5.5-fold lower impact on human health and a 15-fold lower overall environmental impact. CONTACT: To learn more or schedule a media interview, please visit: Eva Criado media@ Marketing & Communications Manager+34 659 188 143 View original content to download multimedia: SOURCE Kensing LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
